Decheng Capital Management Iii (Cayman), LLC Mersana Therapeutics, Inc. Transaction History
Decheng Capital Management Iii (Cayman), LLC
- $181 Million
- Q3 2023
A detailed history of Decheng Capital Management Iii (Cayman), LLC transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Decheng Capital Management Iii (Cayman), LLC holds 904,268 shares of MRSN stock, worth $524,475. This represents 0.64% of its overall portfolio holdings.
Number of Shares
904,268
Previous 904,268
-0.0%
Holding current value
$524,475
Previous $2.98 Million
61.41%
% of portfolio
0.64%
Previous 1.58%
Shares
1 transactions
Others Institutions Holding MRSN
# of Institutions
130Shares Held
104MCall Options Held
58.5KPut Options Held
471K-
Nextech Invest Ag12.1MShares$7 Million3.22% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.3MShares$6.57 Million0.76% of portfolio
-
Vr Adviser, LLC New York, NY10.3MShares$5.95 Million2.42% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$5.02 Million3.35% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$4.86 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $56.4M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...